Alza holds full U.S. marketing rights to the chemotherapy anti-toxicity product from U.S. Bioscience under an agreement through April 2001 (with an option through April 2002). Those rights would transfer to Abbott on completion of its pending purchase of Alza. Under an agreement with Alza, the U.S. Bioscience sales force is co-promoting Ethyol. Alza explained the control of the marketing rights in a letter to "The Pink Sheet" correcting a statement in the Sept. 21 issue (p. 21) which described the Ethyol marketing as a co-promotion agreement
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth